1. Home
  2. SMWB vs GHRS Comparison

SMWB vs GHRS Comparison

Compare SMWB & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SMWB
  • GHRS
  • Stock Information
  • Founded
  • SMWB 2007
  • GHRS 2018
  • Country
  • SMWB Israel
  • GHRS Ireland
  • Employees
  • SMWB N/A
  • GHRS N/A
  • Industry
  • SMWB Computer Software: Programming Data Processing
  • GHRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SMWB Technology
  • GHRS Health Care
  • Exchange
  • SMWB Nasdaq
  • GHRS Nasdaq
  • Market Cap
  • SMWB 624.5M
  • GHRS 583.1M
  • IPO Year
  • SMWB 2021
  • GHRS 2021
  • Fundamental
  • Price
  • SMWB $7.29
  • GHRS $11.74
  • Analyst Decision
  • SMWB Strong Buy
  • GHRS Strong Buy
  • Analyst Count
  • SMWB 8
  • GHRS 8
  • Target Price
  • SMWB $15.75
  • GHRS $30.63
  • AVG Volume (30 Days)
  • SMWB 812.2K
  • GHRS 149.3K
  • Earning Date
  • SMWB 05-13-2025
  • GHRS 05-08-2025
  • Dividend Yield
  • SMWB N/A
  • GHRS N/A
  • EPS Growth
  • SMWB N/A
  • GHRS N/A
  • EPS
  • SMWB N/A
  • GHRS N/A
  • Revenue
  • SMWB $258,017,999.00
  • GHRS N/A
  • Revenue This Year
  • SMWB $16.67
  • GHRS N/A
  • Revenue Next Year
  • SMWB $15.56
  • GHRS N/A
  • P/E Ratio
  • SMWB N/A
  • GHRS N/A
  • Revenue Growth
  • SMWB 15.06
  • GHRS N/A
  • 52 Week Low
  • SMWB $5.71
  • GHRS $6.00
  • 52 Week High
  • SMWB $17.64
  • GHRS $20.50
  • Technical
  • Relative Strength Index (RSI)
  • SMWB 43.42
  • GHRS 59.18
  • Support Level
  • SMWB $7.22
  • GHRS $11.47
  • Resistance Level
  • SMWB $7.66
  • GHRS $13.00
  • Average True Range (ATR)
  • SMWB 0.39
  • GHRS 0.95
  • MACD
  • SMWB 0.00
  • GHRS 0.10
  • Stochastic Oscillator
  • SMWB 14.94
  • GHRS 69.16

About SMWB Similarweb Ltd.

Similarweb Ltd provides a platform for digital intelligence, delivering a trusted, comprehensive, and detailed view of the digital world that empowers customers to accelerate their growth and become more competitive in the markets. Its proprietary technology analyzes billions of digital interactions and transactions every day from millions of websites and apps and turns these digital signals into actionable insights. The company generates revenues mainly from SaaS subscriptions, which comprise subscription fees from customers utilizing cloud-based digital intelligence solutions and other subscription-based solutions. Geographically, the majority of its revenue is derived from the United States and rest from Israel, United Kingdom, Europe, Asia Pacific and other regions.

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Share on Social Networks: